TuHURA Biosciences Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA Biosciences Inc., formerly known as Kintara Therapeutics Inc., is based in SAN DIEGO.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-21.68M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.61 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -248.79% |
| Return on Assets (Trailing 12 Months) | -150.83% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.83 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.83 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.38 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.21 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.21 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 50.05M |
| Free Float | 49.95M |
| Market Capitalization | $145.14M |
| Average Volume (Last 20 Days) | 0.79M |
| Beta (Past 60 Months) | 0.04 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.62% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |